Top

Published in:

01-02-2009 | Parkinson's Disease and Allied Conditions - Short Communication

Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy

Authors: Francesca R. Buttarelli, Annapia Circella, Clelia Pellicano, Dorina Tiple, Morena Giovannelli, Carlo Colosimo, Francesco E. Pontieri

Published in: Journal of Neural Transmission | Issue 2/2009

Abstract

Previous studies showed the reduction of dopamine transporter immunoreactivity (DAT-IR) in peripheral blood lymphocytes (PBL) in Parkinson’s disease. Here we report the reduction of DAT-IR in PBL in the extrapyramidal variant of multiple system atrophy. These results suggest the reduction of DAT-IR in PBL in a variety of neurodegenerative disorders, provided the presence of damage of the central dopaminergic systems. The reduction of DAT-IR in PBL in these disorders may represent a compensatory phenomenon aimed at reducing intracellular dopamine influx and, consequently, dopamine-mediated aggravation of oxidative stress in these cells.

Amenta F, Bronzetti E, Felici L et al (1999) Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J Auton Pharmacol 19:151–159PubMedCrossRef

Amenta F, Bronzetti E, Cantalamessa F et al (2001) Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 117:133–142PubMedCrossRef

Bannon MJ, Whitty CJ (1997) Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 48:969–977PubMed

Barroso N, Campos Y, Huertas R et al (1993) Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson’s disease. Clin Chem 39:667–669PubMed

Battisti C, Formichi P, Radi E et al (2008) Oxidative stress-induced apoptosis in PBLs of two patients with Parkinson’s disease secondary to alpha-synuclein mutation. J Neurol Sci 268:183–186PubMedCrossRef

Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [¹²³I]-FP-CIT SPECT imaging: the [¹²³I]-FP-CIT Study Group. Mov Disord 15:503–510PubMedCrossRef

Bergquist J, Tarkowski A, Ekman R et al (1994) Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci USA 91:12912–12916PubMedCrossRef

Blandini F, Cosentino M, Mangiagalli A et al (2004) Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson’s disease. The effects of dopaminergic treatment. J Neural Transm 111:1017–1030PubMedCrossRef

Blandini F, Sinforiani E, Pacchetti C et al (2006) Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 66:529–534PubMedCrossRef

Borasio GD, Linke R, Schwarz J et al (1998) Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I–123] IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry 65:263–265PubMedCrossRef

Brooks DJ, Frey KA, Marek KL et al (2003) Assessment of neuroimaging techniques as biomarkers of progression of Parkinson’s disease. Exp Neurol 184(suppl. 1):S78–S89

Buttarelli FR, Circella A, Pellicano C et al (2006) Dopamine transporter immunoreactivity in peripheral blood lymphocytes in amyotrophic lateral sclerosis. Eur J Neurol 13:416–418PubMedCrossRef

Buttarelli FR, Capriotti G, Pellicano C et al. (2008) Central and peripheral dopamine transporter reduction in Parkinson’s disease. Neurol Res (in press)

Caronti B, Antonini G, Calderaro C et al (2001) Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson’s disease. J Neural Transm 108:803–807PubMedCrossRef

Caronti B, Tanda G, Colosimo C et al (1999) Reduced dopamine in peripheral blood lymphocytes in Parkinson’s disease. Neuroreport 10:2907–2910PubMedCrossRef

Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRef

Gilman S, Low PA, Quinn N et al (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163:94–98PubMedCrossRef

Jimenez Del Rio M, Velez-Pardo C (2000) 17 beta-Estradiol protects lymphocytes against dopamine and iron-induced apoptosis by a genomic-independent mechanism. Implication in Parkinson’s disease. Gen Pharmacol 35:1–9PubMed

Kim S, Jeon BS, Heo C et al (2004) Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson’s disease. FASEB J 18:1615–1617PubMedCrossRef

Marazziti D, Baroni S, Catena Dell’Osso M et al (2008) Presence and characterization of the dopamine transporter in human resting lymphocytes. Neurochem Res 33:1011–1016PubMedCrossRef

Migliore L, Petrozzi L, Lucetti C et al (2002) Oxidative damage and cytogenetic analysis in leukocytes of Parkinson’s disease patients. Neurology 58:809–815

Pellicano C, Buttarelli FR, Circella A et al (2007) Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor. J Neural Transm 114:935–938PubMedCrossRef

Petrozzi L, Lucetti C, Gambaccini G et al (2001) Cytogenetic analysis of oxidative damage in lymphocytes of Parkinson’s disease patients. Neurol Sci 22:83–84PubMedCrossRef

Ricci A, Bronzetti E, Mignini F et al (1999) Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 96:234–240PubMedCrossRef

Seeberger LC, Hauser RA (2007) Optimizing bioavailability in the treatment of Parkinson’s disease. Neuropharmacology 53:791–800PubMed

Uhl GR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson’s disease. Ann Neurol 43:555–560PubMedCrossRef

Wenning GK, Colosimo C, Geser F et al (2004) Multiple system atrophy. Lancet Neurol 3:93–103PubMedCrossRef

Title: Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy
Authors: Francesca R. Buttarelli
Annapia Circella
Clelia Pellicano
Dorina Tiple
Morena Giovannelli
Carlo Colosimo
Francesco E. Pontieri
Publication date: 01-02-2009
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 2/2009
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-008-0170-0

At a glance: The STEP trials

Springer Medicine

Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

MEG resting state functional connectivity in Parkinson’s disease related dementia

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson’s disease

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review

Acquired stuttering after pallidal deep brain stimulation for dystonia

Metabolism of galactose in the brain and liver of rats and its conversion into glutamate and other amino acids